Alpine Immune Sciences (Nasdaq:ALPN) - Aandelenkoers, Nieuws & Analyse

ALPN Overzicht aandelen

Operates as a clinical-stage biopharmaceutical company.

ALPN fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 34.24% per jaar groeien

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 9.9% per jaar dalen.

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Volatiele aandelenkoers in de afgelopen 3 maanden

Alpine Immune Sciences, Inc. Concurrenten

Zai Lab

NasdaqGM:ZLAB

US$3.0b

Blueprint Medicines

NasdaqGS:BPMC

US$5.8b

Crinetics Pharmaceuticals

NasdaqGS:CRNX

US$5.1b

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Alpine Immune Sciences
Historische aandelenkoersen
Huidige aandelenkoers	US$64.97
52 Week Hoogtepunt	US$65.00
52 Week Laag	US$8.33
Bèta	0.97
11 maand verandering	0.65%
3 maanden verandering	113.79%
1 Jaar Verandering	518.17%
33 jaar verandering	520.53%
5 jaar verandering	1,270.68%
Verandering sinds IPO	580.31%

Recent nieuws en updates

Recent updates

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Apr 11

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Mar 21

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Mar 20

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Mar 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Feb 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Dec 19

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Sep 23

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Aug 09

Alpine: Rest Before Rallying Again

Apr 25

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Apr 12

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Sep 18

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Aug 18

Rendement voor aandeelhouders

	ALPN	US Biotechs	US Markt
7D	0.03%	-1.4%	-1.9%
1Y	518.2%	20.2%	30.4%

Rendement versus industrie: ALPN overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 20.2 % opleverde.

Rendement versus markt: ALPN overtrof de US markt, die het afgelopen jaar een rendement opleverde van 30.4 %.

Prijsvolatiliteit

Is ALPN's price volatile compared to industry and market?
ALPN volatility
ALPN Average Weekly Movement	13.8%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van ALPN is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 14% ) van ALPN is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	142	Mitch Gold	www.alpineimmunesciences.com

Alpine Immune Sciences, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Alpine Immune Sciences zich tot de beurswaarde?
ALPN fundamentele statistieken
Marktkapitalisatie	US$4.46b
Inkomsten(TTM)	-US$36.84m
Inkomsten(TTM)	US$56.52m

78.9x

P/S-verhouding

-121.0x

Koers/Winstverhouding

Is ALPN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ALPN resultatenrekening (TTM)
Inkomsten	US$56.52m
Kosten van inkomsten	US$83.78m
Brutowinst	-US$27.26m
Overige uitgaven	US$9.58m
Inkomsten	-US$36.84m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.54
Brutomarge	-48.23%
Nettowinstmarge	-65.17%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ALPN op de lange termijn?

Bekijk historische prestaties en vergelijking

ALPN Overzicht aandelen

Beloningen

Risicoanalyse

Alpine Immune Sciences, Inc. Concurrenten

NasdaqGM:ZLAB

US$3.0b

NasdaqGS:BPMC

US$5.8b

NasdaqGS:CRNX

US$5.1b

NasdaqGS:TPTX

US$3.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

Consensus estimates of losses per share improve by 20%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

Consensus estimates of losses per share improve by 20%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

New minor risk - Share price stability

Alpine Immune Sciences, Inc Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 10% to US$37.00

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Price target increased by 9.5% to US$33.57

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Price target increased by 11% to US$31.83

Price target increased by 12% to US$30.67

Executive Chairman & CEO exercised options and sold US$1.8m worth of stock

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Executive Chairman & CEO notifies of intention to sell stock

Consensus revenue estimates increase by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $149.9968 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

Alpine Immune Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

New minor risk - Share price stability

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Alpine Immune Sciences, Inc. Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

Consensus estimates of losses per share improve by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Consensus revenue estimates fall by 33%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Alpine Immune Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Consensus forecasts updated

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Price target decreased to US$18.33

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Alpine Immune Sciences, Inc. Provides Clinical Updates for Its Two Wholly Owned Programs, ALPN-303 and davoceticept

Consensus EPS estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Alpine Immune Sciences, Inc. Announces Board Changes

Alpine Immune Sciences Appoints Andrew S. Sandler as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab